AbbVie's Allergan inks $2.3B+ opioid settlement with several states
Less than a week after Teva inked a $4.25 billion deal to settle opioid-related litigation in several states, many of the same states are now touting a similar deal with AbbVie.
AbbVie’s Allergan unit has agreed to pay up to $2.37 billion (including settlements already reached with individual states) to state and local governments affected by the opioid crisis. Together with the Teva deal, that amounts to $6.6 billion in settlement funds nationwide, according to statements released by several attorneys general on Friday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,200+ biopharma pros reading Endpoints daily — and it's free.